S.N. Westin, Kathleen N Moore, H. S. Chon, Jung-Yun Lee, Jessica Thomes Pepin, M. Sundborg, Joseph de la Garza, S. Nishio, Ke Wang, K. Mcintyre, T. Tillmanns, Fernando Contreras Mejia, Andreia Cristina De Melo, Dagmara Klasa-Mazurkewicz, C.A. Papadimitriou, Marta Gil-Martin, B. Brasiuniene, C. Donnelly, Xiaochun Liu, E. Nieuwenhuysen
{"title":"619 作为新诊断的晚期或复发性子宫内膜癌的一线治疗,先用杜伐单抗加卡铂/紫杉醇,再用杜伐单抗±奥拉帕利:DUO-E/GOG-3041/ENGOT-EN10 三期试验的结果","authors":"S.N. Westin, Kathleen N Moore, H. S. Chon, Jung-Yun Lee, Jessica Thomes Pepin, M. Sundborg, Joseph de la Garza, S. Nishio, Ke Wang, K. Mcintyre, T. Tillmanns, Fernando Contreras Mejia, Andreia Cristina De Melo, Dagmara Klasa-Mazurkewicz, C.A. Papadimitriou, Marta Gil-Martin, B. Brasiuniene, C. Donnelly, Xiaochun Liu, E. Nieuwenhuysen","doi":"10.1136/ijgc-2024-esgo.31","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"54 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial\",\"authors\":\"S.N. Westin, Kathleen N Moore, H. S. Chon, Jung-Yun Lee, Jessica Thomes Pepin, M. Sundborg, Joseph de la Garza, S. Nishio, Ke Wang, K. Mcintyre, T. Tillmanns, Fernando Contreras Mejia, Andreia Cristina De Melo, Dagmara Klasa-Mazurkewicz, C.A. Papadimitriou, Marta Gil-Martin, B. Brasiuniene, C. Donnelly, Xiaochun Liu, E. Nieuwenhuysen\",\"doi\":\"10.1136/ijgc-2024-esgo.31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"54 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.31\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.31","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 Trial